王 涛, 杨晓群, 孙娟娟. PTEN protein loss is associated with an increased risk of recurrence in Chinese patients after prostatectomy for clinically localized prostate cancer[J]. China Oncology, 2015, 25(8): 595-601.
王 涛, 杨晓群, 孙娟娟. PTEN protein loss is associated with an increased risk of recurrence in Chinese patients after prostatectomy for clinically localized prostate cancer[J]. China Oncology, 2015, 25(8): 595-601. DOI: 10.3969/j.issn.1007-3969.2015.08.006.
PTEN protein loss is associated with an increased risk of recurrence in Chinese patients after prostatectomy for clinically localized prostate cancer
背景与目的:张力蛋白同源第10号染色体缺失的磷酸酶基因(phosphatase and tensin homolog deleted on chromosome 10,PTEN)缺失是西方国家前列腺癌中最常见的基因异常之一,与肿瘤的进展、预后均有一定相关性。鉴于前列腺癌的异质性,不同地区、人群间其基因表达谱存在广泛差异,本研究主要探讨PTEN蛋白缺失在中国前列腺癌患者中的发生率以及与生化复发的相关性。方法:选取2006—2011年225例局限性前列腺癌并采取根治切除术的患者为研究对象,回顾性收集所有患者的临床病理资料,包括确诊时年龄、血清前列腺特异性抗原(prostate-specific antigen,PSA)值、Gleason分级评分、TNM分期、手术切缘和术后生化复发与否及时间。将225例局限性前列腺癌根治切除标本的肿瘤组织及癌旁组织制成组织芯片(tissue microarray,TMA),采用免疫组织化学技术检测PTEN蛋白在肿瘤及癌旁组织中的表达。采用χ
Background and purpose: Loss of the tumor suppressor phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is one of the most common somatic genetic aberrations in prostate cancer in Western countries and is frequently asso
ciated with tumor progression and poor prognosis. This study aimed to investigate the frequency of PTEN protein loss in Chinese prostate cancer patients and to determine its association with the biochemical recurrence of prostate cancer. Methods: The data from 225 diagnosed localized prostate cancer patients with radical prostatectomy from 2006 to 2011 were collected retrospectively
including patient’s age at diagnosis
prostate-specific antigen (PSA) level at diagnosis
Gleason score
clinical stage
surgical margin
and time to biochemical recurrence or not. This study performed PTEN protein immunohistochemistry on tissue microarrays
which were made from 225 Chinese prostate cancer patients mentioned above
treated by radical prostatectomy with one case including 2 cancer spots and 2 adjacent normal gland spots. Correlations of PTEN loss with clinicopathological features were analyzed using χ
2
test. Kaplan-Meier survival model and Cox proportional hazards regression model were used to evaluate the predictive role of PTEN protein expression and patient characteristics for biochemical recurrence. Results: PTEN protein loss was observed in 15% of the patients and was associated with increased preoperative PSA levels (P=0.03) and old age (P=0.009). In univariate Kaplan–Meier analysis
the factors associated with the biochemical recurrence of prostate cancer included PSA levels (P=0.000 4)
Gleason sum (P=0.019 8)
and PTEN status (P=0.013 1). In multivariable Cox regression analysis
PTEN expression (HR=0.536
P=0.044)
PSA levels (HR=1.879
P=0.001)
and Gleason score (HR=1.361
P=0.03) were significant in predicting biochemical recurrence of prostate cancer. Conclusion: PTEN protein loss is associated with an increased risk of recurrence